Maintenance treatment of duodenal ulcer (DU) with ranitidine 150 mg/day was compared with placebo in a two year prospective multicentre randomised study. Three hundred and ninety nine patients were included (mean age: 44.7 years, M/F ratio=2*47/1; 37-6% of smokers) in placebo (n=202) and ranitidine (n=197) groups. Efficacy was assessed by the length oftime to the first ulcer pain attack (with or without endoscopic confirmation) or DU complication. One hundred and fourteen patients of 399 (28.6%) had incomplete follow up. Actuarial survival curves of patients without ulcer pain (26 and 53% at two years in placebo and ranitidine groups, respectively) were significantly different (p<0O0001). Endoscopies were performed depending on physicians' decision (mainly where there was severe pain or complication). Patients without relapses from endoscopy were more frequent in the ranitidine group (83%) than in the placebo group (47%, p<0O0001). A greater incidence of complications, mainly bleeding, was also seen in the placebo group (13 complications v two in the ranitidine group, p<0002). No factor predicting DU relapse was identified. No important side effect was encountered. Ranitidine 150 mg/day is effective and well tolerated in preventing ulcer pain attacks and DU complications for up to two years.
Accepted for publication 22 April 1993 The efficacy of longterm ('maintenance') treatment of duodenal ulcer (DU) disease with H2 blockers is well established, at least for one year of treatment'"7; review in ref 6 . Less information is available about longer periods and fewer controlled trials ofat least two year duration have been published.8"'5 Two major problems are encountered, however, when one analyses such trials. Firstly, the number of patients lost to follow up is comparatively high, ranging from 20'4 to 70-90%, namely in the placebo groups.9 '5 Secondly, the number of patients included in these trials rarely exceeds 150. This is of critical importance because the criteria for assessing the efficacy of longterm treatment are currently becoming more accurate. If it is expected that longterm treatment should decrease morbidity and mortality related to DU disease, not only should ulcer pain be alleviated for the patient but the incidence ofpotentially serious complications (mainly bleeding) should also be diminished. As calculated in this study (see methods), such an aim needs 200 patients to be studied per group.
Finally, clinical studies should be conducted pragmatically, in conditions resembling as closely as possible current practice. This should limit selection bias and systematic procedures (visits, endoscopies) that would not have been performed otherwise. The aim of this study was to compare the efficacy of ranitidine 150 mg/day and placebo for up to two years in preventing occurrence of ulcer pain and DU complications.
Patients and methods

PATIENTS
Three hundred and ninety nine DU patients without ulcers were included within 15 days of endoscopy in this prospective study. They were randomly allocated to receive either ranitidine 150 mg once daily (n= 197) or placebo (n=202) after dinner for 24 months. Table I shows the patients' main characteristics and they were similar in the two groups except for the proportion of alcohol users. Mean daily alcohol intake, however, was similar in the two groups. Patients with gastric ulcer, Zollinger-Ellison syndrome, gastric surgery, or major organ failure were excluded, as were pregnant women and lactating mothers.
METHODS
The study was undertaken in a prospective randomised double blind, placebo controlled way and was multicentric, with 59 French gastroenterologists participating who were in private or in hospital practice.
Follow up visits were scheduled every three months for 24 months, and whenever symptoms recurred. Treatment failure was defined by recurrence of epigastric pain, identical to pre- Results Thirty six patients (9%) were lost to follow up. Fifty five more patients (13 8%), however, withdrew their consent to participate during the study, most of them at the end of the first year of treatment. In these patients the duration of follow up was thus shorter than the two years initially planned. Table II shows the causes of incomplete follow up in 114/399 patients (28 6%). The length of time to the first episode of pain is shown in Figure 1 and was significantly longer in the ranitidine group than in the placebo group (p<00001). Twenty six per cent and 53% of the patients were free of ulcer pain at two years in the placebo and ranitidine groups, respectively.
Patients free of endoscopic relapse (Fig 2) -47 and 83% of the patients were free of endoscopic .0 E . 
Qt
relapse at two years, in the placebo and ranitidine groups, respectively (p<0*0001). DU complications -15 patients had a DU complication throughout the study, 13 in the placebo group and two in the ranitidine group (Fig 3, p<0 002 ). In the placebo group, 10 patients presented with DU bleeding. Haemorrhage was mild in five cases; five patients required a stay in hospital (mean duration, 12 days); one of them had surgery for persistent bleeding. Three patients had endoscopic stenosis of the duodenal cap, but none had surgery during the study period. In the ranitidine'group, one patient experienced haematemesis because of a bleeding DU, while receiving anticoagulant treatment for thrombophlebitis. DU healed with reinforcement of medical treatment (300 mg/ day); the patient stayed in hospital for nine days and required blood transfusion. Another patient presented with an incomplete stenosis of the duodenal cap at endoscopy and was not operated on.
Predictive factors of DU relapse (Table III) none of the following factors was predictive for DU relapse, either in the placebo or in the ranitidine group: age, sex, smoking, alcohol consumption, duration of DU disease and incidence of recurrences, presence of erosive duodenitis at time of DU healing.
Compliance and adverse events -compliance to medical treatment was assessed by the number of tablets returned at each control visit. Compliance was very satisfactory in both groups (89 and 93% of the tablets were effectively taken in the placebo and ranitidine groups, respectively). Adverse events leading to withdrawal occurred in 10 patients (Table II) , but none was thought by the investigator to be related to the study drug. Minor side effects were seen in 13 (6 4%) and 9 (4 5%) patients in the placebo and ranitidine groups, respectively. '3 On the contrary, the absence of regularly scheduled endoscopies in this study means that the prevalence of asymptomatic ulcers was not assessed. The clinical importance of these ulcers occurring in patients under maintenance treatment is highly questionable,'8 and some studies have shown that their course is to heal or remain asymptomatic, rarely to become symptomatic and even less frequently to become complicated. 9 With the stringent above mentioned criteria, more than one patient of two was relapse free at two years in the ranitidine group (as compared with one of four in the placebo group). Some randomised double blind studies of DU maintenance treatment with H2 blockers for at least two years have been published, either with cimetidine,8I13'5 ranitidine,.1'2'4 or nizatidine.'°I n most ofthem, the number ofpatients included was small or the number of drop outs high. Van Deventer et al found in 140 DU patients (who reentered the maintenance phase after healing of recurrent ulcers), that prophylactic treatment with ranitidine reduced the relapse rate from 63 to 37% after two years of treatment. 14 These data included, however, asymptomatic ulcers found at routine endoscopy at 12 and 24 months (almost two thirds of the ulcers in the ranitidine group and one third in the placebo group, were asymptomatic). On the other hand, pain episodes without endoscopically confirmed DU relapse were not taken into account in this study.
Discussion
A pragmatic protocol, close to the present one, was used by Pym et al with cimetidine (400 mg/ day). ' 
